No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker Astrazeneca said on Wednesday that its Trixeo Aerosphere candidate has been approved in the European Union as a maintenance treatment for asthma in patients aged 12 and over.
Astrazeneca stated Trixeo was now the first and only triplecombination therapy cleared in the EU for this age group, regardless of exacerbation history, with the singleinhaler treatment combining an inhaled corticosteroid, a longacting beta2agonist and a longacting muscarinic antagonist. The drug was already marketed as Breztri Aerosphere in the US, China and Japan.
The European Commission's decision followed a positive opinion from the EMA's CHMP and was supported by results from its Phase III KALOS and LOGOS trials.
Astrazeneca said Trixeo delivered statistically significant improvements in lung function versus dual ICS/LABA comparators. In pooled analyses, it also reduced the annualised rate of severe asthma exacerbations across a broad patient population, including those without exacerbations in the prior year.
As of 1100 BST, Astrazeneca shares were down 0.96% at 12,550p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.